Latest Options News

Hubify has completed a strategic $250,000 placement at a striking 425% premium to fund its AI-first growth strategy, including a key partnership with HubLab to deliver AI-powered ICT and cybersecurity services.

SomnoMed Limited has reported a return to profitability for the half-year ending December 2025, posting a $792,000 net profit after tax on the back of a 13% revenue increase. Despite the positive turnaround, the company has elected not to pay an interim dividend.

Basin Energy has executed a definitive agreement to sell its Marshall Uranium Project to Green Canada Corporation, securing upfront payments and retaining significant future upside through equity and buyback options.

Matrix Composites & Engineering Ltd reported a $9.4 million loss for the half-year ending December 2025, driven by a 32% drop in revenue to $26.9 million. Despite the weak first half, the company anticipates a robust second half to meet or exceed last year’s full-year revenue.

Harvest Technology Group’s half-year report reveals a 50% revenue decline and a widening net loss, offset by a $6 million funding facility and strategic partnerships.

GoldArc Resources has locked in a strategic drilling services agreement with MMS for its Leonora South Gold Project, enabling up to A$750,000 of drilling fees to be paid in shares. This innovative deal preserves cash and aligns contractor incentives with the project’s long-term success.

Activeport Group Ltd reported a 36% revenue decline and a 25% increase in net loss for the half-year ended December 2025, while securing key contracts with Tier 1 telcos and raising $8.8 million in capital.

MinRex Resources Limited (ASX: MRR) has announced a definitive agreement to acquire 100% of Electrum Discovery Corp. (TSX-V: ELY) via a statutory Plan of Arrangement, creating a combined ASX-listed gold-copper exploration company with significant assets in Serbia and Australia.

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

Wesfarmers has updated its dividend details, confirming a fully franked ordinary dividend of AUD 1.02 per share for the half-year ending December 2025, with payment scheduled for March 31, 2026. Shareholders can choose to receive payments in AUD, NZD, or GBP, reflecting the company’s international shareholder base.

Decidr AI Industries Ltd reported a $17.2 million loss for the half-year ending December 2025, reversing a prior profit, while completing full ownership of Decidr.ai and expanding into the US market with Sugarwork Inc.